ArticleScience (New York, N.Y.)2014
HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers.
0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
193 citing papers in PubMed.
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.The Journal of infectious diseases · 2019Trial
- HLA-B*14:02-Restricted Env-Specific CD8Journal of virology · 2017Trial
- Untangling the effects of within-host and between-host natural selection in viruses with applications to evolution of HIV-1 co-receptor usage.Journal of the Royal Society, Interface · 2026Article
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection.Nature communications · 2026Article
- Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques.Journal of virology · 2026Article
- Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Getting to the root of HIV transmitted founder virus sequences.Virus evolution · 2026Article
- Multifaceted B cell response to transient HIV viremia in elite controllers.PLoS pathogens · 2026Article
- Single genome amplification and molecular cloning of HIV-1 populations in acute HIV-1 infection: implications for studies on HIV-1 diversity and evolutionary rate.Virus evolution · 2026Article
- The conformational epitope of a gp41-specific mucosal protective IgA binds to the HIV-1 envelope and neutralizes infection.Acta pharmacologica Sinica · 2025Article
- Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection.bioRxiv : the preprint server for biology · 2025Article
- Viral expansion after transfer is a primary driver of influenza A virus transmission bottlenecks.PLoS biology · 2025Article
- Viral expansion after transfer is a primary driver of influenza A virus transmission bottlenecks.bioRxiv : the preprint server for biology · 2025Article
- Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies.PLoS pathogens · 2025Article
- Subtype AD Recombinant HIV-1 Transmitted/Founder Viruses Are Less Sensitive to Type I Interferons than Subtype D.Viruses · 2025Article
- HIV-1 adapts to HLA class II-associated selection pressure exerted by CD4Science advances · 2025Article
- The genetic architecture of HIV-1 virulence.Virus evolution · 2025Article
- Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1.Nature microbiology · 2024Article
133 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors.
Jonathan M CarlsonMicrosoft Research, Redmond, WA 98052, USA. carlson@microsoft.com ehunte4@emory.edu.
Malinda SchaeferEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Daniela C MonacoEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Rebecca BatorskyRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02114, USA.
Daniel T ClaiborneEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Jessica PrinceEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Martin J DeymierEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Zachary S EndeEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Nichole R KlattEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Charles E DeZielMicrosoft Research, Redmond, WA 98052, USA.
Tien-Ho LinMicrosoft Research, Redmond, WA 98052, USA.
Jian PengMicrosoft Research, Redmond, WA 98052, USA.
Aaron M SeeseRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02114, USA.
Roger ShapiroDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
John FraterNuffield Department of Clinical Medicine, University of Oxford, Oxford OX1 7BN, UK. National Institute of Health Research, Oxford Biomedical Research Centre, Oxford OX3 7LE, UK. Oxford Martin School, University of Oxford, Oxford OX1 3BD, UK.
Thumbi Ndung'uRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02114, USA. HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4013, South Africa. KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4001, South Africa. Max Planck Institute for Infection Biology, D-10117 Berlin, Germany.
Jianming TangDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Paul GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Jill GilmourInternational AIDS Vaccine Initiative, London SW10 9NH, UK. Imperial College of Science Technology and Medicine, London SW10 9NH, UK.
Matt A PriceInternational AIDS Vaccine Initiative, San Francisco, CA 94105, USA. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94105, USA.
William KilembeRwanda-Zambia HIV Research Group: Zambia-Emory HIV Research Project, Lusaka, Zambia.
David HeckermanMicrosoft Research, Los Angeles, CA 98117, USA.
Philip J R GoulderHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4013, South Africa. Department of Paediatrics, University of Oxford, Oxford OX1 3SY, UK.
Todd M AllenRwanda-Zambia HIV Research Group: Zambia-Emory HIV Research Project, Lusaka, Zambia. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Susan AllenInternational AIDS Vaccine Initiative, San Francisco, CA 94105, USA. Microsoft Research, Los Angeles, CA 98117, USA. Department of Paediatrics, University of Oxford, Oxford OX1 3SY, UK.
Eric HunterEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA. Rwanda-Zambia HIV Research Group: Zambia-Emory HIV Research Project, Lusaka, Zambia. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA. carlson@microsoft.com ehunte4@emory.edu.
Funding
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MYNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MCTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7MRecognition of HIV-1 by Innate Immunity Receptors during Primary InfectionP01AI074415 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2008 to 2013
$17.3MVirologic Correlates of Heterosexual TransmissionR37AI051231 · NIAID · EMORY UNIVERSITY · PI HUNTER, ERIC · 2008 to 2017
$9.6MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MOptimizing CD8+ T-cell responses against C clade HIV infection in subSaharan AfriR01AI046995 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2000 to 2014
$6.8MHAART to Prevent HIV Transmission to Infants In BotswanaU01AI066454 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SHAPIRO, ROGER L · 2005 to 2010
$5.3MHIV CTL Escape Mutation and Reversion in Linked PairsF32AI084409 · NIAID · EMORY UNIVERSITY · PI SCHAEFER, MALINDA · 2009 to 2010
$98kHoward Hughes Medical InstituteMedical Research Council G108/626NCRR NIH HHS 2P51RR000165-51NCRR NIH HHS P51 RR000165NCRR NIH HHS P51RR165NIAID NIH HHS F32 AI084409NIAID NIH HHS P01 AI074415NIAID NIH HHS P01-AI074415NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI046995NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI64060NIAID NIH HHS R37 AI051231NIAID NIH HHS R37 AI51231NIAID NIH HHS T32 AI007387NIAID NIH HHS T32-AI007387NIAID NIH HHS U01 AI066454NIAID NIH HHS U01 AI 66454NIH HHS OD P51OD11132NIH HHS P51 OD010425NIH HHS P51 OD011132Wellcome Trust
Abstract
Heterosexual transmission of HIV-1 typically results in one genetic variant establishing systemic infection. We compared, for 137 linked transmission pairs, the amino acid sequences encoded by non-envelope genes of viruses in both partners and demonstrate a selection bias for transmission of residues that are predicted to confer increased in vivo fitness on viruses in the newly infected, immunologically naïve recipient. Although tempered by transmission risk factors, such as donor viral load, genital inflammation, and recipient gender, this selection bias provides an overall transmission advantage for viral quasispecies that are dominated by viruses with high in vivo fitness. Thus, preventative or therapeutic approaches that even marginally reduce viral fitness may lower the overall transmission rates and offer long-term benefits even upon successful transmission.
Indexed as
HeterosexualitySelection, GeneticAmino Acid SequenceConsensus SequenceDisease Transmission, InfectiousDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHuman Immunodeficiency Virus ProteinsHumansMaleModels, StatisticalMolecular Sequence DataPoint MutationHuman Immunodeficiency Virus Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.